Brain

Peer-Reviewed Studies Validate Linus Health AI as an Early Digital Biomarker for Alzheimer’s Pathology, Helping People Take Action Earlier to Slow Disease Impact

Findings show Linus Health's AI can indicate Alzheimer's pathology before noticeable symptoms—enabling earlier action to help protect independence and preserve…

22 hours ago

Remedy’s Nutrition® Launches Mega VMT™ High-Potency Multivitamin to Revolutionize Daily Energy and Nutritional Wellness

KEY LARGO, Fla., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Remedy's Nutrition®, a trusted natural dietary supplement company since 1972 and…

1 day ago

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

Total national coverage footprint for PENFS increases to roughly 100 million covered livesCARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) --…

1 day ago

Glioblastoma Foundation Expands Scientific Leadership as It Prepares to Accept Patient Samples for Universal Genomic Testing

Foundation to offer universal genomic testing for glioblastoma patients DURHAM, NC / ACCESS Newswire / December 18, 2025 / Today,…

2 days ago

Amicus Brain Unveils Amicus INTERACT, an AI App Tackling Dementia-Related Loneliness

Empowering meaningful conversations and preserving independence for people living with dementia  CHAPPAQUA, N.Y., Dec. 18, 2025 /PRNewswire/ -- Amicus Brain…

2 days ago

Amicus Brain Unveils Amicus INTERACT, an AI App Tackling Dementia-Related Loneliness

Empowering meaningful conversations and preserving independence for people living with dementia  CHAPPAQUA, N.Y., Dec. 18, 2025 /PRNewswire/ -- Amicus Brain…

2 days ago

Edison Issues Report on MindMaze Therapeutics (MMTX)

London, United Kingdom--(Newsfile Corp. - December 18, 2025) - Edison issues report on MindMaze Therapeutics (SIX: MMTX).MindMaze Therapeutics is a…

2 days ago

Biodexa Announces Pricing of $10 Million Public Offering

December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”),…

2 days ago

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator,…

2 days ago

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator,…

2 days ago